$8.99
11.68% yesterday
Nasdaq, Dec 03, 10:03 pm CET
ISIN
US00654J1079
Symbol
ADXN

Addex Therapeutics Ltd - ADR Stock price

$8.99
+0.28 3.21% 1M
+0.91 11.26% 6M
+1.99 28.43% YTD
+1.02 12.80% 1Y
-5.47 37.81% 3Y
-202.21 95.74% 5Y
-281.01 96.90% 10Y
-281.01 96.90% 20Y
Nasdaq, Closing price Wed, Dec 03 2025
+0.94 11.68%
ISIN
US00654J1079
Symbol
ADXN
Industry

Key metrics

Basic
Market capitalization
$10.1m
Enterprise Value
$7.2m
Net debt
positive
Cash
$2.9m
Shares outstanding
111.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
14.2 | 10.5
EV/Sales
10.2 | 7.5
EV/FCF
negative
P/B
1.1
Financial Health
Equity Ratio
90.6%
Return on Equity
72.9%
ROCE
-27.3%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$710.0k | $956.9k
EBITDA
$-2.5m | $-4.0m
EBIT
$-2.5m | $-4.1m
Net Income
$-7.1m | $-9.9m
Free Cash Flow
$-1.8m
Growth (TTM | estimate)
Revenue
-34.3% | 87.6%
EBITDA
71.3% | -17.2%
EBIT
71.4% | -19.8%
Net Income
-230.9% | -212.6%
Free Cash Flow
81.6%
Margin (TTM | estimate)
Gross
-
EBITDA
-346.9% | -421.3%
EBIT
-356.4%
Net
-1,002.3% | -1,038.3%
Free Cash Flow
-255.4%
More
EPS
$-0.1
FCF per Share
$0.0
Short interest
0.4%
Employees
23
Rev per Employee
$20.0k
Show more

Is Addex Therapeutics Ltd - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

Addex Therapeutics Ltd - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Addex Therapeutics Ltd - ADR forecast:

2x Hold
22%
7x Sell
78%

Analyst Opinions

9 Analysts have issued a Addex Therapeutics Ltd - ADR forecast:

Hold
22%
Sell
78%

Financial data from Addex Therapeutics Ltd - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
0.71 0.71
34% 34%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 2.36 2.36
51% 51%
332%
- Research and Development Expense 0.79 0.79
79% 79%
111%
-2.45 -2.45
71% 71%
-345%
- Depreciation and Amortization 0.07 0.07
71% 71%
10%
EBIT (Operating Income) EBIT -2.51 -2.51
71% 71%
-354%
Net Profit -7.07 -7.07
231% 231%
-996%

In millions USD.

Don't miss a Thing! We will send you all news about Addex Therapeutics Ltd - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Addex Therapeutics Ltd - ADR Stock News

Neutral
GlobeNewsWire
about 2 hours ago
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 4, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its financial results for the three-month and nine-month periods ended September 30, 2025, and provided a...
Neutral
GlobeNewsWire
3 days ago
Geneva, Switzerland, December 1, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its Third Quarter 2025 Financial Results on December 4, 2025. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Scien...
Neutral
Seeking Alpha
2 months ago
Addex Therapeutics Ltd (NASDAQ:ADXN ) Q2 2025 Earnings Call October 1, 2025 10:00 AM EDT Company Participants Timothy Dyer - Co-Founder, CEO & Director Mikhail Kalinichev - Head of Translational Science Conference Call Participants Bob Pooler - ValuationLAB AG Raghuram Selvaraju - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good day, and thank you for standing by.
More Addex Therapeutics Ltd - ADR News

Company Profile

Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators for neurological disorders. The company was founded by Vincent Mutel, Timothy Dyer, and Mark Epping-Jordan in 2002 and is headquartered in Geneva, Switzerland.

Head office Switzerland
CEO Tim Dyer
Employees 23
Founded 2002
Website www.addextherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today